1,515 results on '"Alexander, G. Caleb"'
Search Results
2. Deprescribing of antidepressants: development of indicators of high-risk and overprescribing using the RAND/UCLA Appropriateness Method
3. Risk of Major Bleeding Associated with Concomitant Direct-Acting Oral Anticoagulant and Clopidogrel Use: A Retrospective Cohort Study
4. Proceedings of the International Ambulatory Drug Safety Symposium: Munich, Germany, June 2023
5. Association between switching to integrase strand transfer inhibitors and incident diabetes in people with HIV: a longitudinal cohort study
6. Generalisable long COVID subtypes: Findings from the NIH N3C and RECOVER programmes
7. Comparative Effectiveness and Safety of Direct Oral Anticoagulants vs Warfarin among Nursing Home Residents with Atrial Fibrillation: A Retrospective Cohort Study
8. Impact of Race on Classification of Atherosclerotic Risk Using a National Cardiovascular Risk Prediction Tool
9. Assessment of the U.S. Food and Drug Administration's risk evaluation and mitigation strategy (REMS) for prasugrel (EFFIENT): A narrative review
10. Economic evaluation reference case with Markov model
11. Generalisable long COVID subtypes: findings from the NIH N3C and RECOVER programmes
12. Noninterventional studies in the COVID-19 era: methodological considerations for study design and analysis
13. Thromboprophylaxis in people hospitalized with COVID‐19: Assessing intermediate or standard doses in a retrospective cohort study
14. Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis
15. Nirmatrelvir/Ritonavir (Paxlovid) Use Among Individuals at Risk of Severe COVID‐19: An Analysis of the National COVID Cohort Collaborative (N3C).
16. Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative
17. Inclusion of Participants with CKD and Other Kidney-Related Considerations during Clinical Drug Development: Landscape Analysis of Anticancer Agents Approved from 2015 to 2019
18. State Variation in Chronic Opioid Use in Long-Term Care Nursing Home Residents
19. Association Between Pharmacy Proximity With Cardiovascular Medication Use and Risk Factor Control in the United States
20. EFFECT OF RACE ON CLASSIFICATION OF ATHEROSCLEROTIC RISK USING A NATIONAL CARDIOVASCULAR RISK PREDICTION TOOL
21. Lower Use of Biologics for the Treatment of Asthma in Publicly Insured Individuals
22. More than two-dozen prescription drug-based risk scores are available for risk adjustment: A systematic review
23. Primary care physicians’ preparedness to treat opioid use disorder in the United States: A cross-sectional survey
24. Comparative Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin Among Adults With Cancer and Atrial Fibrillation
25. The mysterious beauty of ketamine: Benefits and risks
26. Estimating the prevalence of and characteristics associated with prescription opioid diversion among a clinic population living with HIV: Indirect and direct questioning techniques
27. Association Between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products
28. Implementation and enforcement of state opioid prescribing laws
29. Cigarette excise taxes, clean indoor air laws, and use of smoking cessation treatments: A mediation analysis
30. Recreational and Medical Cannabis Legalization and Opioid Prescriptions and Mortality
31. Sociodemograhic and spending characteristics of Medicare beneficiaries taking prescription drugs subject to price negotiations
32. Risk of Major Bleeding Associated with Concomitant Direct-Acting Oral Anticoagulant and Clopidogrel Use: A Retrospective Cohort Study
33. Effects of Prescription Drug Insurance on Hospitalization and Mortality: Evidence From Medicare Part D
34. High-dose opioid utilization and mortality among individuals initiating hemodialysis
35. Correction to: High-dose opioid utilization and mortality among individuals initiating hemodialysis
36. Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study
37. Clinical Development of Biologics Approved by the US Food and Drug Administration, 2003-2016
38. Underrepresentation of black individuals in pivotal trials for novel anticancer drugs: Potential consequence of using estimated creatinine clearance to assess kidney function?
39. Clean indoor air laws, cigarette excise taxes, and smoking: Results from the current population survey-tobacco use supplement, 2003–2011
40. Medicaid trends in prescription opioid and non-opioid use by HIV status
41. The United States Postal Service: an Essential Public Health Agency?
42. Cost-Effectiveness of Lecanemab for Individuals With Early-Stage Alzheimer Disease.
43. Prescribing cascades in ambulatory care: A structured synthesis of evidence
44. Characteristics of Prescription Drug Fills Using Pharmacy-Pharmacy Benefits Manager (PBM) Discount Programs: The “GoodRx” Model
45. Evaluating the Impact of Prescription Fill Rates on Risk Stratification Model Performance
46. Predictors of new persistent opioid use after benign hysterectomy in the United States
47. The Value of U.S. Pharmacopeial Standards: A Review of the Literature
48. Family caregivers’ facilitation of daily adult prescription medication use
49. Exposure– and Dose–response Analyses in Dose Selection and Labeling of FDA-approved Biologics
50. Long-Term Cardiovascular Risks of Psychostimulant Drugs for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.